Product Description
Mechanisms of Action: EPCAM Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Germany
Approved Indications: None
Known Adverse Events: None
Company: Austrian Breast & Colorectal Cancer Study Group
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Colorectal Cancer|Mucinous Cystadenocarcinoma|Mucinous Adenocarcinoma
Phase 2: Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00002664 |
GWCC-5095 | P2 |
Withdrawn |
Colorectal Cancer |
2017-02-22 |
2019-03-21 |
Treatments |
|
NCT00002968 |
NCI-2012-02826 | P3 |
Completed |
Mucinous Cystadenocarcinoma|Mucinous Adenocarcinoma|Colorectal Cancer |
2003-07-01 |
2019-03-21 |
Treatments |
|
NCT00309517 |
ABSCG 92 | P3 |
Terminated |
Colorectal Cancer |
None |
2019-03-21 |
Treatments |